CN102947330B - 二硫键稳定的功能性可溶mhc ii类异二聚体 - Google Patents

二硫键稳定的功能性可溶mhc ii类异二聚体 Download PDF

Info

Publication number
CN102947330B
CN102947330B CN201180011237.4A CN201180011237A CN102947330B CN 102947330 B CN102947330 B CN 102947330B CN 201180011237 A CN201180011237 A CN 201180011237A CN 102947330 B CN102947330 B CN 102947330B
Authority
CN
China
Prior art keywords
molecule
mhc
quasi
molecules
mhc class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180011237.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102947330A (zh
Inventor
吉尔·艾吉·洛塞特
泰耶·弗里格斯塔德
英格·桑德莱
比亚内·博根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitetet i Oslo
Original Assignee
Universitetet i Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitetet i Oslo filed Critical Universitetet i Oslo
Publication of CN102947330A publication Critical patent/CN102947330A/zh
Application granted granted Critical
Publication of CN102947330B publication Critical patent/CN102947330B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201180011237.4A 2010-02-18 2011-02-18 二硫键稳定的功能性可溶mhc ii类异二聚体 Active CN102947330B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30572810P 2010-02-18 2010-02-18
US61/305728 2010-02-18
GBGB1002730.8A GB201002730D0 (en) 2010-02-18 2010-02-18 Product
GB1002730.8 2010-02-18
US31657610P 2010-03-23 2010-03-23
US61/316576 2010-03-23
PCT/GB2011/050325 WO2011101681A2 (en) 2010-02-18 2011-02-18 Disulphide bond-stabilized functional soluble mhc class ii heterodimers

Publications (2)

Publication Number Publication Date
CN102947330A CN102947330A (zh) 2013-02-27
CN102947330B true CN102947330B (zh) 2015-09-16

Family

ID=42113985

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180011237.4A Active CN102947330B (zh) 2010-02-18 2011-02-18 二硫键稳定的功能性可溶mhc ii类异二聚体

Country Status (18)

Country Link
US (2) US8828379B2 (enExample)
EP (1) EP2536746B1 (enExample)
JP (1) JP5537675B2 (enExample)
KR (1) KR101647176B1 (enExample)
CN (1) CN102947330B (enExample)
AU (1) AU2011217027B2 (enExample)
CA (1) CA2789492C (enExample)
CY (1) CY1117697T1 (enExample)
DK (1) DK2536746T3 (enExample)
ES (1) ES2572388T3 (enExample)
GB (1) GB201002730D0 (enExample)
HR (1) HRP20160475T1 (enExample)
HU (1) HUE027952T2 (enExample)
PL (1) PL2536746T3 (enExample)
RS (1) RS54744B1 (enExample)
RU (1) RU2604813C2 (enExample)
SI (1) SI2536746T1 (enExample)
WO (1) WO2011101681A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
CA2865033C (en) 2012-02-23 2021-11-02 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP3511423B2 (en) 2012-10-17 2024-05-29 Spatial Transcriptomics AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
CA2954594A1 (en) * 2014-07-09 2016-01-14 Lupin Limited Dual cistronic bacterial expression system
WO2017004252A1 (en) 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
AU2016341527B2 (en) 2015-10-22 2023-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
JP2020500015A (ja) * 2016-11-09 2020-01-09 ユーティーアイ リミテッド パートナーシップ 組換えｐＭＨＣクラスＩＩ分子
EP4647493A2 (en) 2017-04-27 2025-11-12 Juno Therapeutics, Inc. Oligomeric particle reagents and methods of use thereof
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
WO2020064915A1 (en) * 2018-09-28 2020-04-02 Danmarks Tekniske Universitet High throughput epitope identification and t cell receptor specificity determination using loadable detection molecules
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3719033A1 (en) * 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
WO2021035049A1 (en) * 2019-08-21 2021-02-25 Uti Limited Partnership Improved recombinant pmhc molecules
US20210155670A1 (en) * 2019-09-13 2021-05-27 The Regents Of The University Of California Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications
CA3163549A1 (en) * 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
DE102020109447A1 (de) 2020-04-03 2021-10-07 Jacobs University Bremen Ggmbh Synthetisches mhc-klasse-ii-protein
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN118813436A (zh) * 2023-07-24 2024-10-22 佳吾益(北京)科技有限公司 展示单mhc等位基因功能蛋白的工程化细胞
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞
WO2025137580A1 (en) * 2023-12-22 2025-06-26 Antiger Therapeutics, Inc. Class ii hla with inter-chain disulfide bond

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006749A2 (en) * 1996-08-16 1998-02-19 President And Fellows Of Harvard College Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor
CN1308674A (zh) * 1998-05-19 2001-08-15 阿维德克斯有限公司 多价t细胞受体复合物
CN1708512A (zh) * 2002-08-21 2005-12-14 普罗伊缪因有限公司 嵌合mhc蛋白及其寡聚物
WO2006102170A2 (en) * 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
PT1017721E (pt) * 1997-09-16 2009-05-07 Univ Oregon Health & Science Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio
RU2303264C2 (ru) * 2001-02-19 2007-07-20 Мерк Патент Гмбх Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью
EP2783699A1 (en) * 2003-09-05 2014-10-01 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
AU2007283731B2 (en) 2006-08-11 2013-10-24 Katholieke Universiteit Leuven Immunogenic peptides and their use in immune disorders
EP2097789B1 (en) * 2006-12-01 2012-08-01 Carl Zeiss SMT GmbH Optical system with an exchangeable, manipulable correction arrangement for reducing image aberrations
PL2193199T3 (pl) 2007-08-20 2014-04-30 Nextera As Ekspozycja fagowa pVII

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006749A2 (en) * 1996-08-16 1998-02-19 President And Fellows Of Harvard College Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor
CN1308674A (zh) * 1998-05-19 2001-08-15 阿维德克斯有限公司 多价t细胞受体复合物
CN1708512A (zh) * 2002-08-21 2005-12-14 普罗伊缪因有限公司 嵌合mhc蛋白及其寡聚物
WO2006102170A2 (en) * 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells

Also Published As

Publication number Publication date
EP2536746A2 (en) 2012-12-26
US9056920B2 (en) 2015-06-16
RS54744B1 (sr) 2016-10-31
RU2012138302A (ru) 2014-03-27
KR101647176B1 (ko) 2016-08-09
WO2011101681A3 (en) 2011-12-08
CN102947330A (zh) 2013-02-27
AU2011217027A1 (en) 2012-09-06
US20130171668A1 (en) 2013-07-04
US20140349315A1 (en) 2014-11-27
JP2013519721A (ja) 2013-05-30
WO2011101681A2 (en) 2011-08-25
CA2789492C (en) 2017-04-18
PL2536746T3 (pl) 2016-08-31
SI2536746T1 (sl) 2016-09-30
KR20130009782A (ko) 2013-01-23
CY1117697T1 (el) 2017-05-17
US8828379B2 (en) 2014-09-09
CA2789492A1 (en) 2011-08-25
GB201002730D0 (en) 2010-04-07
AU2011217027B2 (en) 2015-02-05
DK2536746T3 (en) 2016-05-30
JP5537675B2 (ja) 2014-07-02
HUE027952T2 (en) 2016-11-28
ES2572388T3 (es) 2016-05-31
EP2536746B1 (en) 2016-04-20
HRP20160475T1 (hr) 2016-06-03
RU2604813C2 (ru) 2016-12-10

Similar Documents

Publication Publication Date Title
CN102947330B (zh) 二硫键稳定的功能性可溶mhc ii类异二聚体
EP3850363B1 (en) Method for high throughput peptide-mhc affinity screening for tcr ligands by stabilised, peptide-free mhc complexes
Landais et al. New design of MHC class II tetramers to accommodate fundamental principles of antigen presentation
EP1882700B1 (en) Biotinylated MHC complexes and their uses
Justesen et al. Functional recombinant MHC class II molecules and high-throughput peptide-binding assays
KR20160085345A (ko) 조작된 고-친화도의 인간 t 세포 수용체
US20030166057A1 (en) Method and apparatus for the production of soluble MHC antigens and uses thereof
US20240262885A1 (en) Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications
EP3994161A1 (en) Peptide-mhc complexes
BR112021007530A2 (pt) Polipeptídeo que tem uma estrutura helicoidal tripla, proteína de fusão, método para gerar um polipeptídeo que tem uma estrutura helicoidal tripla, composição, método para reduzir a afinidade de ligação de um polipeptídeo que tem uma estrutura helicoidal tripla para o domínio fc de imunoglobulina, e polinucleotídeo
US20240076356A1 (en) Display of peptide-mhc (pmhc) on multimeric protein scaffolds and uses thereof
Wen et al. Cell surface display of functional human MHC class II proteins: yeast display versus insect cell display
WO2021138688A1 (en) Systems and methods for identification of mhc-i peptide epitopes
Moro et al. Generation of functional HLA-DR* 1101 tetramers receptive for loading with pathogen or tumour derived synthetic peptides
Yan et al. Structures and homology modeling of chicken major histocompatibility complex protein class I (BF2 and β2m)
HK1177939B (en) Disulphide bond-stabilized functional soluble mhc class ii heterodimers
Lunde et al. Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins
Fortin et al. MMTV superantigens coerce an unconventional topology between the TCR and MHC class II
Sharma et al. Refolding of HLA-B27 heavy chains in the absence of β2m yields stable high molecular weight (HMW) protein forms displaying native-like as well as non-native-like conformational features: Implications for autoimmune disease
CA2438376A1 (en) Method and apparatus for the production of antigens and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant